Cargando…

Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea

Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Diefenbach-Elstob, Tanya, Guernier, Vanina, Burgess, Graham, Pelowa, Daniel, Dowi, Robert, Gula, Bisato, Puri, Munish, Pomat, William, McBryde, Emma, Plummer, David, Rush, Catherine, Warner, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473227/
https://www.ncbi.nlm.nih.gov/pubmed/30744192
http://dx.doi.org/10.3390/tropicalmed4010033
_version_ 1783412381709238272
author Diefenbach-Elstob, Tanya
Guernier, Vanina
Burgess, Graham
Pelowa, Daniel
Dowi, Robert
Gula, Bisato
Puri, Munish
Pomat, William
McBryde, Emma
Plummer, David
Rush, Catherine
Warner, Jeffrey
author_facet Diefenbach-Elstob, Tanya
Guernier, Vanina
Burgess, Graham
Pelowa, Daniel
Dowi, Robert
Gula, Bisato
Puri, Munish
Pomat, William
McBryde, Emma
Plummer, David
Rush, Catherine
Warner, Jeffrey
author_sort Diefenbach-Elstob, Tanya
collection PubMed
description Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, aiming to identify the proportion of DR-TB, and characterise Mycobacterium tuberculosis (MTB) drug resistance-associated gene mutations. Sputum samples were investigated for MTB infection using published molecular methods. DNA from MTB-positive samples was amplified and sequenced, targeting the rpoB and katG genes to identify mutations associated with rifampicin and isoniazid resistance respectively. A total of 240 sputum samples were collected at Balimo District Hospital (BDH). Of these, 86 were classified as positive based on the results of the molecular assays. For samples where rpoB sequencing was successful, 10.0% (5/50, 95% CI 4.4–21.4%) were considered rifampicin-resistant through detection of drug resistance-associated mutations. We have identified high rates of presumptive DR-TB in the Balimo region of Western Province, PNG. These results emphasise the importance of further surveillance, and strengthening of diagnostic and treatment services at BDH and throughout Western Province, to facilitate detection and treatment of DR-TB, and limit transmission in this setting.
format Online
Article
Text
id pubmed-6473227
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64732272019-04-29 Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea Diefenbach-Elstob, Tanya Guernier, Vanina Burgess, Graham Pelowa, Daniel Dowi, Robert Gula, Bisato Puri, Munish Pomat, William McBryde, Emma Plummer, David Rush, Catherine Warner, Jeffrey Trop Med Infect Dis Article Papua New Guinea (PNG) has a high burden of tuberculosis (TB), including drug-resistant TB (DR-TB). DR-TB has been identified in patients in Western Province, although there has been limited study outside the provincial capital of Daru. This study focuses on the Balimo region of Western Province, aiming to identify the proportion of DR-TB, and characterise Mycobacterium tuberculosis (MTB) drug resistance-associated gene mutations. Sputum samples were investigated for MTB infection using published molecular methods. DNA from MTB-positive samples was amplified and sequenced, targeting the rpoB and katG genes to identify mutations associated with rifampicin and isoniazid resistance respectively. A total of 240 sputum samples were collected at Balimo District Hospital (BDH). Of these, 86 were classified as positive based on the results of the molecular assays. For samples where rpoB sequencing was successful, 10.0% (5/50, 95% CI 4.4–21.4%) were considered rifampicin-resistant through detection of drug resistance-associated mutations. We have identified high rates of presumptive DR-TB in the Balimo region of Western Province, PNG. These results emphasise the importance of further surveillance, and strengthening of diagnostic and treatment services at BDH and throughout Western Province, to facilitate detection and treatment of DR-TB, and limit transmission in this setting. MDPI 2019-02-10 /pmc/articles/PMC6473227/ /pubmed/30744192 http://dx.doi.org/10.3390/tropicalmed4010033 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Diefenbach-Elstob, Tanya
Guernier, Vanina
Burgess, Graham
Pelowa, Daniel
Dowi, Robert
Gula, Bisato
Puri, Munish
Pomat, William
McBryde, Emma
Plummer, David
Rush, Catherine
Warner, Jeffrey
Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title_full Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title_fullStr Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title_full_unstemmed Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title_short Molecular Evidence of Drug-Resistant Tuberculosis in the Balimo Region of Papua New Guinea
title_sort molecular evidence of drug-resistant tuberculosis in the balimo region of papua new guinea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473227/
https://www.ncbi.nlm.nih.gov/pubmed/30744192
http://dx.doi.org/10.3390/tropicalmed4010033
work_keys_str_mv AT diefenbachelstobtanya molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT guerniervanina molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT burgessgraham molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT pelowadaniel molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT dowirobert molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT gulabisato molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT purimunish molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT pomatwilliam molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT mcbrydeemma molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT plummerdavid molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT rushcatherine molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea
AT warnerjeffrey molecularevidenceofdrugresistanttuberculosisinthebalimoregionofpapuanewguinea